ClinicalTrials.gg
RecruitingNCT07482384SHIELDUpdated Aug 10, 2026

Supporting Health Including Endocrine Treatment for Long Duration

An interventional study of SHIELD portal in Breast Cancer, Breast Cancer - Female and Breast Carcinoma, sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute — 15 open to participants now, 43 under way, none of them phase 3. Breast Neoplasms · Dana-Farber Cancer Institute.

Planned enrollment
92nd of 132
30 · median 50
Started
2026
with 3 others
No phase
52 of 142
6 open now
Primary completion
2027-01
later than 21 of 42 live
Registered
137th of 142
by date

Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, this one is the 92nd largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2026, is one of 52 with no phase, reaches primary completion later than 21 of the 42 other live ones, and was the 137th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.

Read the detailed description

This research study is a single-arm intervention pilot study to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease prescribed long-term endocrine treatment. The SHIELD portal is designed to help monitor the frequency and variation in cancer and treatment-related issues and to share self-management information and resources to those interested in particular issues or who indicate a specific concern, symptom or side effect on measures designed to assess and track salient symptoms.

Research study procedures include screening for eligibility, in-clinic and virtual approaches for recruitment, gaining access and using the SHIELD web- and mobile app-based supportive care portal, and completing of survey assessments on the SHIELD portal.

Participation in this research study is expected to last 3 months.

It is expected that 30 people will take part in this research study.

03

Conditions studied

  • Breast Cancer
  • Breast Cancer - Female
  • Breast Carcinoma
  • ER Positive Breast Cancer
  • PR-Positive Breast Cancer

Browse trials for

Keywords

  • Breast cancer
  • Breast cancer female
  • Breast carcinoma
  • ER+
  • SHIELD
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants will be eligible if they meet the following eligibility criteria:

  • Female
  • Age 18-49 years at diagnosis of a stage 0-IIIa, HR+ breast cancer
  • Premenopausal
  • In active treatment (including long-term endocrine therapy) at the time of enrollment
  • Able to speak, understand and read English
  • Access to a US-based mobile phone number
  • Cognitively able to complete study requirements
  • Ability to access medical records from treating hospital (DFCI)
  • Willing to provide cell phone number and/or email address and willing to receive email, mobile push notifications, and/or text messages from the study team

Exclusion criteria

Exclusion criteria

Participants will be ineligible if they meet any of the following criteria:

  • Individuals under age 18 or over age 50 at initial breast cancer diagnosis
  • Stage IV or breast cancer
  • Pregnant patients
  • Individuals who do not have a US mobile phone number
  • Males with breast cancer are not being recruited to this protocol. In the adolescent and young adult (AYA) age group, only a miniscule proportion of breast cancers occur in males. Additionally, this pilot focuses on breast cancer treatment utilizing OFS and ET, both of which do not apply to males. For this reason, the SHIELD portal intervention materials have been targeted for young women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    SHIELD Portal Interventional

    320 participants will be enrolled and will complete the following: Baseline visit (assessments) either by in-person clinic visit or virtually Follow-Up/Post Baseline (3-month assessments) Medical record review (if necessary)

    Behavioral: SHIELD portal

Interventions

  • BehavioralSHIELD portal

    All participants will receive access to the SHIELD portal. The portal includes educational modules, symptom and side effect tracking, tailored informational resources, and health behavior tools. Participants can access the portal via smartphone, tablet, or computer. The portal is HIPAA compliant and HITRUST certified.

    Also known as: Supporting Health Including Endocrine Treatment for Long Duration (SHIELD) Portal

06

What researchers measure

Primary outcomes

  1. Enrollment Yield

    Enrollment yield is defined as the proportion of participants approached for the study intervention (SHIELD, Supporting Health Including Endocrine Treatment for Long Duration) who enroll.

    Time frame: up to 3 weeks

Secondary outcomes

  1. Assessment Completion Rate

    Assessment completion rate is defined as the proportion of assessments completed to assessments offered.

    Time frame: Up to 3 months

  2. Patient Information Resources Access Rate

    Patient information resources access rate is defined as the proportion of patient information resources accessed to the total number delivered.

    Time frame: Up to 3 months

  3. SHIELD Portal Access

    The number of times the SHIELD portal is accessed per month.

    Time frame: Up to 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication.

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Data sharing details ↗ · www.dana-farber.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 5 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 19, 2026
StartActual
Aug 4, 2026
Primary completionEst.
Jan 2027
CompletionEst.
May 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07482384
Collaborators
Breast Cancer Research Foundation
Responsible party
Ann H. Partridge, MD, MPH (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Mar 19, 2026
Start date
Aug 4, 2026
Primary completion
Jan 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Ann H Partridge, MD, MPH
Contact
ann_partridge@dfci.harvard.edu
617-632-6800
Kate Dibble, Ph.D.
Contact
katee_dibble@dfci.harvard.edu
617-582-8294
Ann H Partridge, MD, MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion